Gonadorelin

Gonadorelin is a synthetic 10-amino-acid peptide identical to native gonadotropin-releasing hormone (GnRH) produced by the hypothalamus. Delivered in brief pulses that mimic the natural hypothalamic rhythm, gonadorelin stimulates pituitary GnRH receptors to drive LH and FSH release. The response is frequency-dependent, not simply dose-dependent: continuous or high-dose GnRH-receptor occupancy paradoxically desensitizes and downregulates the receptor and suppresses LH and FSH instead of raising them — the same effect that lets long-acting GnRH agonists shut down the gonadal axis. This is why therapeutic gonadorelin had to be given by pulsatile pump rather than as a steady infusion., with downstream effects on gonadal steroid production. Gonadorelin was the active ingredient in Factrel (gonadorelin hydrochloride, NDA 018123), an FDA-approved product for the diagnostic evaluation of pituitary gonadotropic function; Drugs@FDA now lists Factrel as discontinued. Gonadorelin is widely used in research contexts and incorporated into hormone replacement and testosterone-restart protocols.

Source: FACTREL (gonadorelin hydrochloride) — NDA 018123, — (Hikma; orig. Ayerst/Wyeth), via Drugs@FDA

What is Gonadorelin and how does the GnRH mechanism work?

Gonadorelin is a synthetic 10-amino-acid peptide identical in sequence to native gonadotropin-releasing hormone (GnRH, also LHRH), produced by the hypothalamus and acting on the pituitary GnRH receptor to stimulate LH and FSH release in pulsatile fashion. This downstream gonadotropin signal drives testicular testosterone production (in males) and ovarian follicular development and ovulation (in females). The short native half-life (3–10 minutes) and need for pulsatile administration to avoid pituitary desensitization are the key pharmacokinetic constraints.

Evidence level: established endocrinology; FDA-approved as Factrel (diagnostic); extensive clinical research base across reproductive endocrinology

What does the clinical evidence show for Gonadorelin?

Gonadorelin's clinical evidence base spans diagnostic evaluation of pituitary gonadotropic function (the Factrel approved indication), pulsatile administration via infusion pump for hypothalamic hypogonadism and ovulation induction, and adjunctive use in testosterone replacement therapy (TRT) protocols to maintain endogenous testicular function. The TRT adjunctive use has expanded in functional medicine and men's health practice, often replacing or complementing hCG (human chorionic gonadotropin) for testicular function preservation during exogenous testosterone therapy.

Evidence level: FDA-approved diagnostic; extensive clinical research; established endocrinology practice including TRT adjunctive use

How does Gonadorelin compare to other reproductive endocrine peptides?

Gonadorelin acts at the pituitary GnRH receptor — downstream of Kisspeptin (which stimulates the hypothalamic GnRH neurons that produce native gonadorelin/GnRH).

What are the documented side effects of Gonadorelin?

Gonadorelin has an extensive clinical safety record with mild side effects — injection-site reactions, occasional transient flushing, and rare hypersensitivity reactions. The short half-life and physiological mechanism mean side effects are generally less pronounced than with sustained GnRH analogs (which produce paradoxical pituitary desensitization through receptor downregulation). Long-term safety at sustained intermittent dosing in TRT-adjunctive use is reasonably well-characterized in clinical practice contexts.

Evidence level: extensive clinical safety; TRT-adjunctive long-term use in clinical practice; rare hypersensitivity well-documented

What is the regulatory status of Gonadorelin?

Two gonadorelin products were FDA-approved, and both are now listed as discontinued in Drugs@FDA. Factrel (gonadorelin hydrochloride, NDA 018123) was approved on September 30, 1982 for the diagnostic evaluation of pituitary gonadotropic function. Lutrepulse (gonadorelin acetate, NDA 019687, an orphan drug from Ferring) was approved on October 10, 1989 as a pulsatile-infusion therapy to induce ovulation in women with primary hypothalamic amenorrhea. The FDA record gives no date or reason for either discontinuation, so their removal cannot be attributed to any specific cause. It is currently available in the US through compounding pharmacies under 503A and 503B regulations, with the compounding pharmacy pathway depending on FDA regulatory status that has been in flux during 2024–2026. Internationally, gonadorelin has approved status in several jurisdictions for fertility and hypogonadism indications. Current status in FDA peptide regulation 2025–2026 timeline.

Sources: FACTREL (gonadorelin hydrochloride) — NDA 018123, — (Hikma; orig. Ayerst/Wyeth), via Drugs@FDA; LUTREPULSE KIT (gonadorelin acetate) — NDA 019687, — (Ferring), via Drugs@FDA

Why does Gonadorelin vendor verification matter?

Gonadorelin is widely sold across pharmacy-compounded and research-grade supply chains with substantial quality variance — and the structural similarity to GnRH analogs (leuprolide, triptorelin) requires mass spectrometry verification. Independent HPLC purity testing is the standard quality signal. Pharmacy-grade compounded gonadorelin (for TRT-adjunctive use) carries different quality assurance than research-grade material. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Gonadorelin vendors?

Peptigrity collects independent third-party Certificates of Analysis for gonadorelin from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate.

Frequently asked questions

What does Gonadorelin do?

Gonadorelin stimulates the pituitary GnRH receptor to drive LH and FSH release in pulsatile fashion, with downstream effects on gonadal steroid production. Clinical uses include diagnostic evaluation, fertility/ovulation induction, and adjunctive testosterone replacement therapy for testicular function preservation.

Is Gonadorelin FDA-approved?

Historically, yes — two products. Factrel (gonadorelin hydrochloride, NDA 018123) was FDA-approved in 1982 for diagnostic evaluation of pituitary function, and Lutrepulse (gonadorelin acetate, NDA 019687) was approved in 1989 for pulsatile ovulation induction. Drugs@FDA now lists both as discontinued, and the agency publishes no date or reason for the discontinuation — so we do not characterize why either left the market. Gonadorelin itself remains available in the US through 503A/503B compounding pharmacies.

Sources: FACTREL (gonadorelin hydrochloride) — NDA 018123, — (Hikma; orig. Ayerst/Wyeth), via Drugs@FDA; LUTREPULSE KIT (gonadorelin acetate) — NDA 019687, — (Ferring), via Drugs@FDA

Is Gonadorelin legal to purchase?

Compounded gonadorelin is available through US compounding pharmacies (503A/503B) under physician prescription. Research-grade gonadorelin is legal to purchase as a research chemical for laboratory use in most jurisdictions. Country breakdown in peptide legal status guide.

Why is Gonadorelin used in TRT protocols?

Exogenous testosterone administration suppresses endogenous LH production through negative feedback, which can lead to testicular atrophy and reduced sperm production. Gonadorelin (mimicking natural GnRH pulses) stimulates pituitary LH release and maintains testicular function. This use is well-established in functional medicine and men's health practice though not specifically FDA-approved for this indication.

How does Gonadorelin differ from hCG?

Gonadorelin acts at the pituitary GnRH receptor (one step upstream); hCG acts directly at the testicular LH receptor (one step downstream). Both maintain testicular function during exogenous testosterone therapy but through different mechanisms. Gonadorelin produces a more physiological pattern; hCG produces direct LH-receptor stimulation.

How can I verify a Gonadorelin vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation distinguishing gonadorelin from GnRH analogs. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Gonadorelin dose?

No. Gonadorelin clinical use protocols vary by indication — pulsatile pump infusion for fertility, intermittent subcutaneous dosing for TRT-adjunctive use, single-dose IV for diagnostic evaluation. Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Gonadorelin was FDA-approved as Factrel (discontinued from US market 2020) and is currently available through US compounding pharmacies. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.